CONSTELLA CAPSULE

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

LINACLOTIDE

Διαθέσιμο από:

ABBVIE CORPORATION

Φαρμακολογική κατηγορία (ATC):

A06AX04

INN (Διεθνής Όνομα):

LINACLOTIDE

Δοσολογία:

290MCG

Φαρμακοτεχνική μορφή:

CAPSULE

Σύνθεση:

LINACLOTIDE 290MCG

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

30

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

MISCELLANEOUS GI DRUGS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0155070002; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2013-12-02

Αρχείο Π.Χ.Π.

_CONSTELLA (linaclotide) _
_Page 1 of 37 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CONSTELLA
®
Linaclotide capsules
Capsules of 72 mcg, 145 mcg and 290 mcg linaclotide, for oral use
Guanylate Cyclase-C Agonist (ATC Code: A06AX04)
AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, Quebec
H4S 1Z1
Date of Initial Authorization:
DEC 02, 2013
Date of Revision:
OCT 13, 2022
Submission Control Number: 267569
_CONSTELLA (linaclotide) _
_Page 2 of 37 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, 7.1.2 Breast-feeding
07/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................... 4
4
DOSAGE AND ADMINISTRATION
................................................................................
5
4.1
Dosing Considerations
.............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
........................................................ 5
4.4
Administration
....................................................